What changed for Prostate Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Prostate Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 758 to 781 (+23)
- Late-stage (Phase 3) trials 68 to 69 (+1)
- Trials on record 4,242 to 4,348 (+106)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Prostate Cancer in July 2026. Voxsanity tracks 3 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 210 trials tracked for Prostate Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04743934 · results posted 20 July 2026
According to the results reported on ClinicalTrials.gov, this trial involved 44 men in total — 23 received flibanserin combined with androgen deprivation therapy (ADT, a hormone treatment commonly used for prostate cancer), and 21 received a placebo (an inactive dummy treatment) combined with ADT. The trial was measuring whether flibanserin — a medication sometimes used for low sexual desire — had any effect on sexual activity and sexual quality of life in men receiving ADT. Most participants completed the study: 22 out of 23 in the flibanserin group and 19 out of 21 in the placebo group. The...
-
NCT02217709 · results posted 25 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 26 people, all of whom received the study drug phenelzine sulfate (a tablet taken by mouth). Twenty of the 26 participants completed the study, while six did not finish. The trial was measuring whether the drug could lower levels of PSA — a protein in the blood often used to monitor prostate cancer — in men with recurrent prostate cancer, and also looked at certain side effects and whether the cancer could be seen to progress on scans. The reported data shows that, out of 26 participants, 1 person had their PSA level...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04565457 · results posted 6 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04565457) enrolled 43 people in total — 32 receiving photon radiation therapy and 11 receiving proton radiation therapy. The trial was comparing two types of CT scanning technology used during radiation treatment planning: a standard cone-beam CT (CBCT) scanner and a research version of the same scanner fitted with a special grid designed to improve image quality. The study measured how accurately each scanner captured tissue density and image clarity, which matters because doctors rely on these scans to plan and guide rad...
-
NCT04262154 · results posted 24 April 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 28 people across two groups — 20 participants in Cohort 1 and 8 participants in Cohort 2. The trial was measuring what researchers called a "failure-free rate at 2 years." In this context, "failure" was defined as a rise in a specific blood marker (biochemical failure), signs of disease progression on scans, or death from any cause. The trial was tracking how many participants reached the two-year point without any of these events occurring. The reported data shows that in Cohort 1, 13 out of 20 participants were eva...
-
NCT05764005 · results posted 6 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05764005) involved 35 participants across two groups — 17 people used an intervention website called MAP (Management of Active surveillance in Prostate Cancer) and 18 people used a control website called MUSIC. The trial was a feasibility study, meaning it was designed to test whether a larger study would be practical to run — not to draw firm conclusions about the tool itself. It looked at things like whether enough people could be recruited, whether participants completed the surveys, and whether participants found the w...
-
NCT04288687 · results posted 4 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04288687) enrolled 11 participants, all of whom completed the study. The trial was investigating a drug called niraparib, used as a maintenance therapy (ongoing treatment after an initial treatment phase) for prostate cancer. The main thing researchers were measuring was how many participants were still alive and had no signs of their cancer visibly growing on scans at the six-month mark — a measure known as radiographic progression-free survival at six months. The reported data shows that 6 out of 11 participants met tha...
-
NCT05551117 · results posted 9 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05551117) enrolled 192 participants across two parts and tested a treatment called MGC018 in people with prostate cancer. The main part of the trial (Part 1) compared two different doses of MGC018 — 2.0 mg (91 participants) and 2.7 mg (90 participants) — against a control group (7 participants). A much smaller Part 2 enrolled just 4 participants. The trial was primarily measuring how many people showed no sign of their cancer spreading on scans at six months (called "radiographic progression-free survival"), as well as how...
-
NCT04497844 · results posted 22 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04497844) enrolled 348 participants in each group — one group received niraparib combined with abiraterone acetate plus prednisone, and the other received a placebo combined with abiraterone acetate plus prednisone. The trial was studying men with prostate cancer that had spread, focusing on participants whose tumours had certain gene changes (called HRR gene mutations, including a specific type called BRCA mutations). The main thing being measured was how long participants went without their cancer visibly growing or spre...
-
NCT03503344 · results posted 21 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03503344) enrolled 26 people with prostate cancer, split evenly into two groups of 13. One group received a drug called apalutamide on its own (Arm A), while the other group received apalutamide combined with a focused radiation treatment called stereotactic body radiotherapy, or SBRT (Arm B). All 26 participants completed the study. The main thing the trial was measuring was the proportion of participants whose prostate-specific antigen (PSA) — a protein in the blood often used to monitor prostate cancer — fell to an unde...
-
NCT05457257 · results posted 19 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05457257) enrolled 43 men with prostate cancer — 29 received olaparib (300 mg twice daily) and 14 received an "investigator's choice" of a standard hormone-blocking medicine (called a next-generation hormonal agent, or NHA). The trial was primarily measuring how long participants went without their cancer visibly growing or spreading on scans — a period called "radiological progression-free survival." Several secondary measurements were also tracked, including overall survival, PSA (prostate-specific antigen) levels in the...
-
NCT04446117 · results posted 18 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04446117) enrolled 575 people with prostate cancer — 289 assigned to the experimental group receiving a combination of two medicines called cabozantinib and atezolizumab, and 286 assigned to the control group receiving a standard hormonal therapy (either abiraterone or enzalutamide). The trial was measuring two main things: how long participants went without their cancer visibly growing or spreading on scans (called "progression-free survival"), and how long participants lived overall ("overall survival"). The reported da...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05470699 · results posted 17 December 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 34 participants and was designed to test the imaging performance of a specialised radiotherapy machine called the X1 RefleXion Medical Radiotherapy System (RMRS). The machine has a built-in PET-CT scanner — a type of medical imaging that can detect areas of activity in the body. Participants received both a standard PET-CT scan using a tracer called \[18F\]-DCFPyL (which targets prostate cancer cells) and a PET-CT scan performed on the X1 machine itself. Of the 34 people who started the trial, 20 completed it and 14 d...
-
NCT05696444 · results posted 25 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 137 people across three types of robotic-assisted urological surgery using a system called Hugo: 55 people had a prostatectomy (removal of the prostate), 29 had a cystectomy (removal of the bladder), and 53 had a nephrectomy (removal of a kidney). The trial was measuring how often the robotic surgery could be completed without needing to switch to a different surgical approach, as well as tracking complications and other details about how the operations went. The reported data shows that 134 out of 137 participants c...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05407311 · results posted 17 November 2025
According to the results reported on ClinicalTrials.gov, this trial tested an investigational imaging agent called 64Cu-SAR-BBN — a radioactive tracer designed to be used in PET scans. The trial enrolled 53 participants, of whom 43 completed the study and 10 did not. The trial was measuring two main things: how often side effects occurred, and how accurately the tracer identified true positive findings (areas of disease correctly detected by the scan) compared to a reference standard. Scans were taken on two separate days — Day 0 and Day 1 — to compare how the images looked at different time p...
-
NCT05220501 · results posted 10 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05220501) involved three groups of men undergoing prostate biopsy. A total of 802 participants started the study across the three groups: 137 in the microultrasonography-only group, 263 in the microultrasonography-plus-MRI group, and 402 in the MRI-plus-conventional ultrasound group. The trial was measuring how often each imaging-guided biopsy approach detected a type of prostate cancer considered clinically significant (defined as Gleason Grade Group 2 or higher — a way of classifying how abnormal cancer cells look under...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03507608 · results posted 16 October 2025
According to the results reported on ClinicalTrials.gov, this trial involved a total of 19 people across two phases. In the first phase, 6 participants received the drug flutamide in an open-label "run-in" period (meaning everyone knew what they were taking). Then, in the second phase, 19 participants were randomly assigned in a blinded way (meaning neither the participants nor the researchers knew who was getting what) to receive either flutamide (14 people) or a placebo — a dummy treatment with no active ingredient (5 people). All 19 people in the second phase completed the trial. The trial...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03217747 · results posted 14 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03217747) enrolled a total of 114 participants spread across 14 different treatment groups. The groups tested different combinations and timing schedules involving a drug called avelumab (a type of immunotherapy) sometimes alongside chemotherapy and/or radiation therapy (referred to as XRT), across Arms A through F. The trial was primarily designed to look at whether certain serious side effects — called dose-limiting toxicities, or DLTs — occurred during the early part of treatment. Researchers also tracked whether partic...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04158245 · results posted 22 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04158245) enrolled 9 people, all of whom had a form of advanced prostate cancer that had spread to other parts of the body and was no longer responding to standard hormone treatment. The trial was measuring how well a specialised type of scan — called an 18F-fluciclovine PET scan — could track changes in participants' cancer after they started certain treatments. Participants had one scan before starting treatment and another scan 12 weeks later. Eight of the 9 participants completed the study; one did not complete it, tho...
-
NCT04702737 · results posted 12 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04702737) enrolled 41 people in a single group receiving a drug called tarlatamab, with 40 of them actually receiving the treatment. Only 1 participant was recorded as completing the study, while 40 did not complete it — though the data does not explain the reasons for this in detail. The trial was primarily measuring how many participants experienced unwanted medical events (called adverse events) after receiving tarlatamab, as well as looking at how the cancer responded to the treatment. The reported data shows that all...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05590793 · results posted 9 September 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 195 people, all of whom received a single injection of a 6-month formulation of triptorelin pamoate — a hormone-based treatment used in prostate cancer care. Of those who started, 188 completed the trial and 7 did not. The trial was primarily measuring whether the treatment could lower a hormone called testosterone to what doctors call "castrate level" (below 50 nanograms per deciliter in the blood), and whether that low level could be maintained over time. It also tracked changes in a prostate-related protein in the...
-
NCT03317990 · results posted 4 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03317990) enrolled 407 men in total — 204 in the NeuroSAFE group and 203 in the standard (control) group — who were undergoing robotic-assisted surgical removal of the prostate. Of those, 190 and 191 respectively went on to have surgery, and around 174 in each group completed the trial. The trial was measuring erectile function at 12 months as its main goal, along with bladder control and cancer-related outcomes as secondary goals. The NeuroSAFE procedure involves an additional step during prostate surgery intended to guid...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05458856 · results posted 23 July 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a medication called triptorelin embonate (22.5 mg), given by injection, in men whose treatment required lowering testosterone to very low levels (sometimes called "castrate" levels). A total of 147 participants started the trial, 145 received the treatment, and 134 completed the study. The trial tracked testosterone levels in the blood at several set points over roughly 12 months to see how many participants maintained testosterone below a specific threshold (50 ng/dL, a standard cut-off used in this type of treatmen...
-
NCT03448458 · results posted 17 July 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 17 people, with 16 completing the study and 1 not completing it. The trial used a specialised type of medical scan called a Gallium Ga 68-DOTATATE PET/CT scan — a imaging technique that can detect certain proteins on tumour cells — to look at how much of the scan's tracer was taken up by different areas of disease in participants. The goal was to examine whether the level of tracer uptake seen on the scan was linked to how long participants went without their disease progressing. The reported data shows that, when lo...
-
NCT05547386 · results posted 9 July 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 163 people, all of whom received a PET/CT scan using a radioactive tracer called 68Ga-PSMA-11 (a substance that can help make prostate cancer cells visible on a scan). Of the 163 who started, 156 completed the study, and 7 did not complete it. The trial was observational, meaning researchers were watching and recording what happened rather than testing a new treatment. The main thing being measured was whether any participants experienced unexpected unwanted reactions after being injected with the tracer, from the tim...
-
NCT05288166 · results posted 27 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05288166) enrolled 463 people in the abemaciclib group and 462 people in the placebo group — a total of 925 participants — all of whom had prostate cancer. The trial was measuring several things over time, including how long participants went without their cancer visibly progressing on scans (called radiographic progression-free survival), how long before their cancer became resistant to hormone-lowering treatment, how long they survived overall, how long before pain got worse, and how their quality of life changed. The r...
-
NCT04461509 · results posted 29 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04461509) looked at whether advanced imaging techniques — specifically a type of MRI called high-resolution MRI (hrMRI) and a type of PET scan using a tracer called 18F-PSMA — could find prostate cancers that a standard MRI scan might miss. The trial had two groups: one group of 29 people who were due to have a procedure called HIFU (High-Intensity Focused Ultrasound, which uses sound waves to target prostate tissue), and another group of 33 people who were due to have surgical removal of the prostate (called a radical pro...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02875223 · results posted 20 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02875223) tested a drug called CC-90011 across two parts. In Part A, the trial enrolled 50 people across nine different dose levels — ranging from 1.25 mg up to 120 mg — to find out how much of the drug could be given before serious side effects (called "dose-limiting toxicities," meaning harmful reactions that occur within the first treatment cycle and set the upper limit of a safe dose) became too common. Part B enrolled a further 25 people across four specific cancer groups (lung neuroendocrine tumours, a prostate cance...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04383210 · results posted 3 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04383210) enrolled a total of 54 participants, split across three groups: Cohort 1 (36 people), Cohort 2 (11 people), and Cohort 3 (7 people). All participants who started the trial also completed it — none dropped out. The trial was measuring something called the "objective response rate," which refers to the proportion of participants whose tumours showed a meaningful reduction in size (either disappearing completely or shrinking by at least 30%) as measured by standard medical imaging such as CT or MRI scans. The repor...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05680675 · results posted 6 February 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 50 participants across three groups. Fifteen people were in a group receiving two types of PET/CT scans using FDG and Cu64-DOTATATE tracers, another 15 received FDG and Ga68-DOTATATE scans, and 20 received FDG and PSMA scans. A PET/CT scan is a type of medical imaging that takes detailed pictures of the inside of the body. All participants in every group completed the study — no one dropped out. The trial's main purpose was to collect imaging data that could be used to develop new techniques for combining two differen...
-
NCT01540994 · results posted 16 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT01540994) enrolled 12 participants, all of whom completed the study — none dropped out. The trial involved a single group of people who received a type of targeted radiation treatment for prostate cancer called Stereotactic Body Radiation Therapy (SBRT), which delivers precisely aimed, high-dose radiation over a small number of sessions. The trial was measuring two main things: first, any side effects affecting the urinary tract or lower bowel (both during and after treatment), scored on a standard scale from 0 to 5 where...
See all 210 reported results for Prostate Cancer
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, prostate cancer currently attracts a very large amount of public research investment from the United States government, and that investment has remained broadly steady over recent years. For patients, this signals that prostate cancer is a well-established research priority with sustained scientific attention behind it. A stable funding picture generally means ongoin...
See the full Prostate Cancer page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.